The two posters are titled:
“Does Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation Provide Analgesia Beyond Application Site?”
This poster is a re-analysis of previously published data that further confirms the widespread analgesic effects of Quell® neurostimulation. The abstract is available at:
“Levels and Predictors of Activity in Users of Wearable Neurostimulators with Chronic Pain.”
This poster leverages the unique data that is collected in the Quell Health Cloud to explore activity levels in Quell users. A decrease in activity is associated with chronic pain and contributes to further pain and poor health. Over half of the Quell users in the study dataset walked more than 1 mile (2000 steps) daily while wearing their device indicating that many Quell users are active while receiving therapy. The abstract is available at:
"We are pleased to have the opportunity to present additional Quell data at AAPM, which is one of the premier scientific and clinical meetings in pain medicine,” said
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the
information, please visit NeuroMetrix.com.
SVP and Chief Financial Officer
Source: NeuroMetrix, Inc.